Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a report issued on Thursday morning.

Oramed Pharmaceuticals Stock Up 0.9 %

Shares of ORMP stock opened at $2.21 on Thursday. The company’s 50 day moving average is $2.36 and its 200 day moving average is $2.38. The firm has a market cap of $89.09 million, a price-to-earnings ratio of 20.09 and a beta of 1.66. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BML Capital Management LLC boosted its position in Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after purchasing an additional 837,153 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Oramed Pharmaceuticals during the third quarter valued at about $272,000. Dimensional Fund Advisors LP boosted its holdings in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after buying an additional 10,774 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 9,242 shares in the last quarter. Finally, Marquette Asset Management LLC purchased a new position in shares of Oramed Pharmaceuticals in the 4th quarter worth approximately $81,000. 12.73% of the stock is owned by institutional investors.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.